Up-and-coming pharmacotherapeutic options for treating patients with refractory overactive bladder

This is the authors' abstract. We don't add key points for this paper.

INTRODUCTION: agonist medications. Anticholinergics are known to have high rates of discontinuation due to side effects and there are concerns regarding anticholinergic load and its impact on cognitive function in older adults. AREAS COVERED: This paper aims to discuss the current and emerging treatment options available for patients who suffer from OAB. EXPERT OPINION: The management of OAB in the clinical setting remains challenging. The goal of newer pharmacotherapies in OAB would be treatment that provides long-term symptomatic relief with minimal side effects and an improved quality of life. The future of OAB research is promising and should consider the implications of the gut-bladder axis, regenerative medicine, biomarkers and the role of digital health.